To enhance the Process of Research and Development of Drug Candidates
Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners, Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived products that its U.S. subsidiary FUJIFILM Cellular Dynamics Inc. (FCDI) offers and Axcelead’s compound evaluation and analytical services, the companies will work towards developing new drug efficacy evaluation methods and toxicity testing to meet specific needs of clients.
Tokyo, June 1, 2019 ― FUJIFILM Corporation (President: Kenji Sukeno) will accelerate the development of next-generation cancer immunotherapeutic drug candidates by harnessing the self-renewal potential of allogenic induced pluripotent stem cells (iPSCs). FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human iPSCs and tissue-specific cells differentiated from iPSCs, and Versant Venture Management,…
hiPSC-derived microglia are utilized with the aim of advancing research to fulfill unmet medical needs for patients with neurodegenerative diseases
MADISON, Wis., January 08, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and tissue-specific cells differentiated from iPSCs, has announced the launch of its newest product, iCell® Microglia. Microglia are the immune cells of the central nervous system responsible for fundamental physiological and pathological processes. Differentiated from human iPSCs, iCell Microglia will be used in life science research to enable the study and development of therapies for degenerative neurological diseases such as Alzheimer’s disease…
Fujifilm is investing in the cGMP-compliant facility located in Madison, Wisconsin with the goal to begin operations by March 2020
MADISON, Wis., January 3, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno) and a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21 million to open a new cGMP-compliant production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products.
FUJIFILM Cellular Dynamics, Inc., licenses University of California – Irvine’s technologies for derivation of microglia
MADISON, Wis., June 6, 2018— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. The license of UCI’s groundbreaking technology enables FCDI to differentiate pluripotent stem cells into microglia cells, a brain cell type that plays a critical role in preserving the function of the brain. With this technology, FCDI intends to develop an iPSC-derived microglia product with media, which will be critical to enabling the study of degenerative neurological diseases such as Alzheimer’s disease.
February 8, 2018 – FUJIFILM Corporation (“Fujifilm”, President: Kenji Sukeno) and Takeda Pharmaceutical Company Ltd., (“Takeda”, CEO: Christophe Weber) today announced a collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure.
MADISON, Wis., Dec. 27, 2017 — Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity.
Madison, Wisconsin, September 20, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of differentiated cells derived from human induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH (Nanion), a leading provider of instrumentation for ion channel drug discovery and screening, announced today that they have entered into a joint marketing agreement. The mutual partnership will offer research customers access to CDI’s suite of human iPSC-derived tissue cells paired with the high performance instrument platforms from Nanion to drive functional readouts on human cell models.
MADISON, Wis. — Cellular Dynamics International (CDI), a FUJIFILM company, today announced that it will host the iForum® 2017 meetings at The Buck Institute (Novato, CA) on September 14, 2017, Harvard Medical School (Boston, MA) on September 21, 2017, and at Imperial College (London, U.K.) on September 28, 2017. The annual iForum meetings provide attendees with an opportunity to connect with thought leaders from academia, government, biotech, and pharma to discover new applications and innovative uses for differentiated induced pluripotent stem cells (iPSC) through interactive, data-driven presentations.
Madison, Wisconsin, April 19, 2017— Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cells (iPS), today announced it has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry. The objective of the new partnership is to increase the availability of iPS cells and services to the HSCI network and the research community at large.